Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
- 1 January 1992
- journal article
- Published by Elsevier in The Lancet
- Vol. 339 (8785) , 71-85
- https://doi.org/10.1016/0140-6736(92)90997-h
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial.Journal of Clinical Oncology, 1990
- Estrogen Receptor-Mediated Direct and Indirect Antitumor Effects of TamoxifenJNCI Journal of the National Cancer Institute, 1990
- Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients With Node-Negative Breast CancerJNCI Journal of the National Cancer Institute, 1990
- Menopause and Risk Factors for Coronary Heart DiseaseNew England Journal of Medicine, 1989
- ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERSThe Lancet, 1989
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988
- Secondary prevention of vascular disease by prolonged antiplatelet treatmentBMJ, 1988
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and designBritish Journal of Cancer, 1976
- Prophylactic oophorectomy in breast cancer therapy: A preliminary reportThe American Journal of Surgery, 1969